Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy
Paul M L Janssen, Jason D Murray, Kevin E Schill, Neha Rastogi, Eric J Schultz, Tam Tran, Subha V Raman, Jill A Rafael-Fortney, Paul M L Janssen, Jason D Murray, Kevin E Schill, Neha Rastogi, Eric J Schultz, Tam Tran, Subha V Raman, Jill A Rafael-Fortney
Abstract
Duchenne muscular dystrophy (DMD) is an inherited disease that causes striated muscle weakness. Recently, we showed therapeutic effects of the combination of lisinopril (L), an angiotensin converting enzyme (ACE) inhibitor, and spironolactone (S), an aldosterone antagonist, in mice lacking dystrophin and haploinsufficient for utrophin (utrn(+/-);mdx, het mice); both cardiac and skeletal muscle function and histology were improved when these mice were treated early with LS. It was unknown to what extent LS treatment is effective in the most commonly used DMD murine model, the mdx mouse. In addition, current standard-of-care treatment for DMD is limited to corticosteroids. Therefore, potentially useful alternative or additive drugs need to be both compared directly to corticosteroids and tested in presence of corticosteroids. We evaluated the effectiveness of this LS combination in the mdx mouse model both compared with corticosteroid treatment (prednisolone, P) or in combination (LSP). We tested the additional combinatorial treatment containing the angiotensin II receptor blocker losartan (T), which is widely used to halt and treat the developing cardiac dysfunction in DMD patients as an alternative to an ACE inhibitor. Peak myocardial strain rate, assessed by magnetic resonance imaging, showed a negative impact of P, whereas in both diaphragm and extensor digitorum longus (EDL) muscle contractile function was not significantly impaired by P. Histologically, P generally increased cardiac damage, estimated by percentage area infiltrated by IgG as well as by collagen staining. In general, groups that only differed in the presence or absence of P (i.e. mdx vs. P, LS vs. LSP, and TS vs. TSP) demonstrated a significant detrimental impact of P on many assessed parameters, with the most profound impact on cardiac pathology.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Goyenvalle A, Seto JT, Davies KE, Chamberlain J (2011) Therapeutic approaches to muscular dystrophy. Hum Mol Genet 20: R69–78.
- Merlini L, Gennari M, Malaspina E, Cecconi I, Armaroli A, et al. (2012) Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up. Muscle Nerve 45: 796–802.
- Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, et al. (1989) Randomized, double-blind six-month trial of prednisone in Duchenne’s muscular dystrophy. N Engl J Med 320: 1592–1597.
- Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, et al. (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9: 77–93.
- Fenichel GM, Florence JM, Pestronk A, Mendell JR, Moxley RT 3rd, et al. (1991) Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 41: 1874–1877.
- Machado DL, Silva EC, Resende MB, Carvalho CR, Zanoteli E, et al. (2012) Lung function monitoring in patients with duchenne muscular dystrophy on steroid therapy. BMC Res Notes 5: 435.
- Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, et al. (1983) Clinical investigation in Duchenne dystrophy: 2. Determination of the “power” of therapeutic trials based on the natural history. Muscle Nerve 6: 91–103.
- Henricson E, Abresch R, Han JJ, Nicorici A, Goude Keller E, et al... (2013) The 6-minute walk test and person-reported outcomes in boys with duchenne muscular dystrophy and typically developing controls: longitudinal comparisons and clinically-meaningful changes over one year. PLoS Curr 5.
- Mazzone E, Martinelli D, Berardinelli A, Messina S, D’Amico A, et al. (2010) North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord 20: 712–716.
- McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, et al. (2010) The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve 41: 500–510.
- Muntoni F (2003) Cardiomyopathy in muscular dystrophies. Curr Opin Neurol 16: 577–583.
- Sanyal SK, Johnson WW, Thapar MK, Pitner SE (1978) An ultrastructural basis for electrocardiographic alterations associated with Duchenne’s progressive muscular dystrophy. Circulation 57: 1122–1129.
- Hagenbuch SC, Gottliebson WM, Wansapura J, Mazur W, Fleck R, et al. (2010) Detection of progressive cardiac dysfunction by serial evaluation of circumferential strain in patients with Duchenne muscular dystrophy. Am J Cardiol 105: 1451–1455.
- Bauer R, Straub V, Blain A, Bushby K, MacGowan GA (2009) Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy. Eur J Heart Fail 11: 463–471.
- Rafael-Fortney JA, Chimanji NS, Schill KE, Martin CD, Murray JD, et al. (2011) Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice. Circulation 124: 582–588.
- Zhou L, Rafael-Fortney JA, Huang P, Zhao XS, Cheng G, et al. (2008) Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation and fibrosis in mdx mice. J Neurol Sci 264: 106–111.
- Bulfield G, Siller WG, Wight PA, Moore KJ (1984) X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci U S A 81: 1189–1192.
- Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, et al. (1989) The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 244: 1578–1580.
- Murray JD, Canan BD, Martin CD, Stangland JE, Rastogi N, et al. (2012) The force-temperature relationship in healthy and dystrophic mouse diaphragm; implications for translational study design. Front Physiol 3: 422.
- Rodino-Klapac LR, Janssen PM, Montgomery CL, Coley BD, Chicoine LG, et al. (2007) A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy. J Transl Med 5: 45.
- Martin PT, Xu R, Rodino-Klapac LR, Oglesbay E, Camboni M, et al. (2009) Overexpression of Galgt2 in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild type mice. Am J Physiol Cell Physiol 296: C476–488.
- Peterson JM, Kline W, Canan BD, Ricca DJ, Kaspar B, et al. (2011) Peptide-Based Inhibition of NF-kappaB Rescues Diaphragm Muscle Contractile Dysfunction in a Murine Model of Duchenne Muscular Dystrophy. Mol Med 17: 508–515.
- De Luca A (2012) Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overview. Acta Myol 31: 40–47.
- Guerron AD, Rawat R, Sali A, Spurney CF, Pistilli E, et al. (2010) Functional and molecular effects of arginine butyrate and prednisone on muscle and heart in the mdx mouse model of Duchenne Muscular Dystrophy. PLoS One 5: e11220.
- Sali A, Guerron AD, Gordish-Dressman H, Spurney CF, Iantorno M, et al. (2012) Glucocorticoid-treated mice are an inappropriate positive control for long-term preclinical studies in the mdx mouse. PLoS One 7: e34204.
- van der Hooft CS, Heeringa J, Brusselle GG, Hofman A, Witteman JC, et al. (2006) Corticosteroids and the risk of atrial fibrillation. Arch Intern Med 166: 1016–1020.
- Payne JR, Kotwinski PJ, Montgomery HE (2004) Cardiac effects of anabolic steroids. Heart 90: 473–475.
- McMurray JJ, Pfeffer MA, Swedberg K, Dzau VJ (2004) Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? Circulation 110: 3281–3288.
- Bish LT, Yarchoan M, Sleeper MM, Gazzara JA, Morine KJ, et al. (2011) Chronic losartan administration reduces mortality and preserves cardiac but not skeletal muscle function in dystrophic mice. PLoS One 6: e20856.
- Spurney CF, Sali A, Guerron AD, Iantorno M, Yu Q, et al. (2011) Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. J Cardiovasc Pharmacol Ther 16: 87–95.
- Janssen PML, Hiranandani N, Mays TA, Rafael-Fortney JA (2005) Utrophin deficiency worsens cardiac contractile dysfunction present in dystrophin-deficient mdx mice. Am J Physiol Heart Circ Physiol 289: H2373–2378.
- Beastrom N, Lu H, Macke A, Canan BD, Johnson EK, et al... (2011) mdx(5cv) Mice Manifest More Severe Muscle Dysfunction and Diaphragm Force Deficits than Do mdx Mice. Am J Pathol.
- Chandrasekharan K, Yoon JH, Xu Y, Devries S, Camboni M, et al. (2010) A Human-Specific Deletion in Mouse Cmah Increases Disease Severity in the mdx Model of Duchenne Muscular Dystrophy. Sci Transl Med 2: 42ra54.
Source: PubMed